Aligos Therapeutics

Price & Volume

Stats

52W Range	$6.76-$30
Market Cap	$66.3M
Shares Short	121,295

Financials

Revenue (12 Mos)	$5.9M
Revenue Growth (YoY)	-60.8%
Gross Profit (12 Mos)	-$71.1M
Diluted EPS	-$7.25

News

Yahoo Finance • 12 months ago

13 Stocks Insiders are Buying Now

Yahoo Finance • last year

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Yahoo Finance • last year

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Yahoo Finance • last year

Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)

About

CEO	Dr. Lawrence M. Blatt MBA, Ph.D.
CFO	Ms. Lesley Ann Calhoun CPA
Address	One Corporate Drive, South San Francisco, CA, United States, 94080
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	68